City
Epaper

Pfizer initially rejected BioNTech's offer to develop Covid vaccine

By IANS | Updated: September 13, 2021 19:15 IST

London, Sep 13 US drug maker Pfizer wrongly assumed that the coronavirus outbreak would be quickly contained and ...

Open in App

London, Sep 13 US drug maker Pfizer wrongly assumed that the coronavirus outbreak would be quickly contained and thus declined the offer made by BioNTech to develop a vaccine against the infectious disease that has so far claimed more than 4 million lives globally.

Germany-based BioNTech, now capitalised at US$84 billion, helmed by Turkish couple Dr Ugur Sahin and his wife Dr Ozlem Tureci, were given a "no" by the pharmaceutical giant as the virus was starting to sweep the globe in January 2020, the Telegraph reported.

"Guys, this is not going to work, they were told by Dr Phil Dormitzer, Pfizer's Vice President and Chief Scientific Officer for vaccines. Dormitzer also considered it to be too experimental," the report said.

"My working assumption was that it (Covid-19) would be controlled" like the SARS and MERS outbreaks, Dormitzer later confirmed.

It is because Dormitzer had been involved with discussions about whether to create vaccines for MERS and SARS, only to see the pathogens quickly contained.

However, it was only a "matter of time" before Pfizer changed its mind and a deal was announced between the two companies a month later.

So far, about 1.4 billion doses of Pfizer and BioNTech two-dose revolutionary Covid jab, developed based on mRNA technology, has been shipped to more than 120 countries.

BioNTech founders revealed the story of initial rejection by Pfizer in a new book titled The Vaccine, written by journalist Joe Miller, to be released this week, the report said.

It also accounts how the couple, who emigrated to Germany from Turkey as small children and met on a cancer ward as young doctors, built not one billion-dollar biotech company but two. And how they gambled everything to pivot BioNTech to focus exclusively on a Covid vaccine in early 2020, it added.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: BioNTech SEJoe millerusLondonPremier of saPfizerAdministrative capitalPfizer inc.Pfizer india
Open in App

Related Stories

InternationalColorado Nightclub Raid: Over 100 Illegal Immigrants Detain at Underground Nightclub in US; Video Surfaces

BusinessGlobal Tech Firms Eye India for Manufacturing Amid US-China Tensions

InternationalIllinois Plane Crash: 4 Killed After Cessna C180G Aircraft Goes Down After Hitting Power Lines in Trilla

NationalPM Narendra Modi Discusses Tech and Innovation Collaboration With Elon Musk

InternationalCalifornia Shooting: 6 People Injured in Firing Outside Barbershop in Stockton

Health Realted Stories

HealthJabalpur’s newborn gets life-saving heart treatment under Rashtriya Bal Swasthya Karyakram

HealthCovid-19 vaccines have no lasting impact on metabolic health: Study

HealthNew tech using body fluids to make accurate diagnosis of arthritis in just 10 minutes

HealthNew biosensor platform to detect preeclampsia in pregnant women in 30 minutes

HealthUnion Minister hails launch of Ayushman Vay Vandana Card in Delhi, elderly thank govt